Virus tracking in kidney transplants may spot hidden risks
NCT ID NCT04189835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 509 kidney transplant recipients to see if regularly measuring Epstein-Barr virus (EBV) levels in blood could predict serious infections, a type of cancer called PTLD, or death. Researchers compared virus levels in whole blood versus plasma to find the best way to monitor patients. The goal was to learn whether persistent EBV DNA could signal that a patient's immune system is too suppressed, helping doctors personalize treatment in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Central Region Denmark, Denmark
-
Odense University Hospital
Odense, Region Syddanmark, Denmark
-
Rikshospitalet, Oslo Universitetssykehus
Oslo, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shield young hearts from transplant complications?
- Immune cells engineered to hunt viruses show promise for transplant kids
- Supercharged immune cells take on Drug-Resistant infections
- Donor cells take on Drug-Resistant viruses in new trial
- New drug combo targets Post-Transplant cancer in early trial
- Smart radiation: new trial aims to zap lingering lymphoma cells